MedPath

A Multicenter, Randomized, Double-Blind, Parallel Arm, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients with Metabolic Syndrome and Hypercholesterolemia at High Risk for Coronary Heart Disease. - N/A

Phase 1
Conditions
Hypercholesterolemia
MedDRA version: 8.1 Level: LLT Classification code 10020604 Term: Hypercholesterolemia
Registration Number
EUCTR2006-006497-17-GR
Lead Sponsor
Merck & Co. Inc
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Not specified
Target Recruitment
1120
Inclusion Criteria

Patient has a diagnosis of metabolic syndrome and hyperclosterolemia.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Patients with screening lab values/findings outside required ranges.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath